News

Key partnership formed to create the Myeloma Genome Project

Celgene, the Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences (UAMS) have announced that they have partnered to create the Myeloma Genome Project to compile high quality genetic and clinical data to improve diagnosis, prognosis and treatment for myeloma patients. The aim is to develop a strategy for classifying myeloma into subgroups…

Details

Study reveals prevalence of symptoms in myeloma patients

A Myeloma UK funded study, published recently in the European Journal of Haematology, has found that a large number of symptoms occur frequently in myeloma patients, highlighting the importance of routine assessments throughout the disease trajectory in order to achieve optimal quality of life for patients. Led by Christina Ramsenthaler and Prof Irene Higginson, Department of…

Details

Revamped Cancer Drugs Fund launched in England

A revised Cancer Drugs Fund (CDF) together with wider changes in the way the National Institute for Health and Care Excellence (NICE) assesses cancer drugs has recently been launched. Developed through a partnership between National Health Service (NHS) England and NICE, the new CDF allows drugs which meet set criteria under a managed access agreement…

Details

IMWG publishes updated consensus criteria for response and MRD in myeloma

The International Myeloma Working Group (IMWG) has recently published further consensus criteria for defining disease response in myeloma. Since the original response criteria were set in 2006, newer, more sensitive methods can now quantify myeloma cells as low as 1 in a million. Published in the Lancet Oncology, the updated criteria identify responses beyond complete response…

Details

New genetic clues help explain inherited predisposition to myeloma

A study published recently in Nature Communications has identified eight new genetic risk loci for myeloma, providing further insights into the genetic and biological basis of its predisposition. The research, performed at The Institute of Cancer Research (ICR) and part funded by Myeloma UK involved a meta-analysis of pooled data from several independent genome-wide association…

Details